Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2018, Article ID 3681590, 14 pages
https://doi.org/10.1155/2018/3681590
Research Article

Cellular and Biophysical Pipeline for the Screening of Peroxisome Proliferator-Activated Receptor Beta/Delta Agonists: Avoiding False Positives

1Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), 13083-970 Campinas, SP, Brazil
2Graduate Program in Biosciences and Technology of Bioactive Products, Institute of Biology, State University of Campinas (Unicamp), Campinas, SP, Brazil

Correspondence should be addressed to Ana Carolina Migliorini Figueira; rb.mepnc.oibnl@arieugif.ana

Received 29 September 2017; Revised 22 January 2018; Accepted 5 February 2018; Published 12 April 2018

Academic Editor: Stéphane Mandard

Copyright © 2018 Natália Bernardi Videira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Michalik, J. Auwerx, J. P. Berger et al., “International union of pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Aleshin, M. Strokin, M. Sergeeva, and G. Reiser, “Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: review and novel hypotheses,” Neurochemistry International, vol. 63, no. 4, pp. 322–330, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Iwashita, Y. Muramatsu, T. Yamazaki et al., “Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo,” The Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 1087–1096, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Michalik and W. Wahli, “Involvement of PPAR nuclear receptors in tissue injury and wound repair,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 598–606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. F. A. H. Batista, D. B. B. Trivella, A. Bernardes et al., “Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding,” PLoS ONE, vol. 7, no. 5, Article ID e33643, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. N. S. Tan, M. Vázquez-Carrera, A. Montagner, M. K. Sng, H. Guillou, and W. Wahli, “Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ,” Progress in Lipid Research, vol. 64, pp. 98–122, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. W. R. Oliver Jr., J. L. Shenk, M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Müller, “PPARβ/δ in human cancer,” Biochimie, vol. 136, pp. 90–99, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. T. A. Ajith and T. G. Jayakumar, “Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease,” Clinical and Experimental Pharmacology and Physiology, vol. 43, no. 7, pp. 649–658, 2016. View at Publisher · View at Google Scholar
  10. A. S. Grewal, M. Beniwal, D. Pandita, B. S. Sekhon, and V. Lather, “Recent Updates on peroxisome proliferator-activated receptor δ agonists for the treatment of metabolic syndrome,” Medicinal Chemistry, vol. 12, no. 1, pp. 3–21, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Montagner, W. Wahli, and N. S. Tan, “Nuclear receptor peroxisome proliferator activated receptor (PPAR) β/δ in skin wound healing and cancer,” in European Journal of Dermatology, vol. 25, pp. 4–11, 1 edition, 2015. View at Google Scholar
  12. F. Biscetti, G. Straface, D. Pitocco, F. Zaccardi, G. Ghirlanda, and A. Flex, “Peroxisome proliferator-activated receptors and angiogenesis,” Nutrition, Metabolism & Cardiovascular Diseases, vol. 19, no. 11, pp. 751–759, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Varga, Z. Czimmerer, and L. Nagy, “PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation,” Biochimica et Biophysica Acta, vol. 1812, no. 8, pp. 1007–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Zhang, X. Liu, X.-B. Xie, X.-C. Cheng, and R.-L. Wang, “Multitargeted bioactive ligands for PPARs discovered in the last decade,” Chemical Biology & Drug Design, pp. 635–663, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Matsuura, K. Gamo, H. Miyachi et al., “γ-Mangostin from garcinia mangostana pericarps as a dual agonist that activates both PPARα and PPARδ,” Bioscience, Biotechnology, and Biochemistry, vol. 77, no. 12, pp. 2430–2435, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. L. Takacs and B. D. Abbott, “Activation of mouse and human peroxisome proliferator-activated receptors (α, β/δ, γ) by perfluorooctanoic acid and perfluorooctane sulfonate,” Toxicological Sciences, vol. 95, no. 1, pp. 108–117, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. Z.-N. Xia, Y.-X. Lin, L.-X. Guo et al., “Development of a cell-based high-throughput peroxisome proliferator- activated receptors (PPARs) screening model and its application for evaluation of the extracts from Rhizoma Coptis,” Journal of Asian Natural Products Research, vol. 15, no. 3, pp. 225–234, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. G. S. Grover, B. A. Turner, C. N. Parker, J. Meier, D. S. Lala, and P. H. Lee, “Multiplexing nuclear receptors for agonist identification in a cell-based reporter gene high-throughput screen,” Journal of Biomolecular Screening, vol. 8, no. 3, pp. 239–246, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Seimandi, G. Lemaire, A. Pillon et al., “Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands,” Analytical Biochemistry, vol. 344, no. 1, pp. 8–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Fan and K. V. Wood, “Bioluminescent assays for high-throughput screening,” ASSAY and Drug Development Technologies, vol. 5, no. 1, pp. 127–136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Paguio, P. Stecha, K. V. Wood, and F. Fan, “Improved dual-luciferase reporter assays for nuclear receptors,” Current Chemical Genomics, vol. 4, no. 1, pp. 43–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-H. Zhang, T. D. Y. Chung, and K. R. Oldenburg, “A simple statistical parameter for use in evaluation and validation of high throughput screening assays,” Journal of Biomolecular Screening, vol. 4, no. 2, pp. 67–73, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. F. H. Niesen, H. Berglund, and M. Vedadi, “The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability,” Nature Protocols, vol. 2, no. 9, pp. 2212–2221, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Cervera, S. Gutiérrez, F. Gòdia, and M. M. Segura, “Optimization of HEK 293 cell growth by addition of non-animal derived components using design of experiments,” BMC Proceedings, vol. 5, no. Suppl 8, p. P126, 2011. View at Publisher · View at Google Scholar
  25. C. Ekambomé Basséne, F. Suzenet, N. Hennuyer et al., “Studies towards the conception of new selective PPARβ/δ ligands,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 17, pp. 4528–4532, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at Publisher · View at Google Scholar · View at Scopus
  27. A. C. M. Figueira, D. M. Saidemberg, P. C. T. Souza et al., “Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange,” Molecular Endocrinology, vol. 25, no. 1, pp. 15–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Hamuro, S. J. Coales, J. A. Morrow et al., “Hydrogen/deuterium-exchange (H/D-Ex) of PPARγ LBD in the presence of various modulators,” Protein Science, vol. 15, no. 8, pp. 1883–1892, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Pissios, I. Tzameli, P. J. Kushner, and D. D. Moore, “Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding,” Molecular Cell, vol. 6, no. 2, pp. 245–253, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Rastinejad, P. Huang, V. Chandra, and S. Khorasanizadeh, “Understanding nuclear receptor form and function using structural biology,” Molecular Endocrinology, vol. 51, no. 3, pp. T1–T21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Cimmperman, L. Baranauskiene, S. Jachimovičiute et al., “A quantitative model of thermal stabilization and destabilization of proteins by ligands,” Biophysical Journal, vol. 95, no. 7, pp. 3222–3231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Bagchi Bhattacharjee and S. M. Paul Khurana, “In vitro reporter assays for screening of chemicals that disrupt androgen signaling,” Journal of Toxicology, vol. 2014, Article ID 701752, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Lai, X. Jiang, and X. Li, “Development of luciferase reporter-based cell assays,” ASSAY and Drug Development Technologies, vol. 4, no. 3, pp. 307–315, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. K. DeSantis, A. Reed, R. Rahhal, and J. Reinking, “Use of differential scanning fluorimetry as a high-throughput assay to identify nuclear receptor ligands,” Nuclear Receptor Signaling, vol. 10, p. e002, 2012. View at Google Scholar · View at Scopus
  36. S. Zorrilla, B. Garzón, and D. Pérez-Sala, “Selective binding of the fluorescent dye 1-anilinonaphthalene-8-sulfonic acid to peroxisome proliferator-activated receptor γ allows ligand identification and characterization,” Analytical Biochemistry, vol. 399, no. 1, pp. 84–92, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Hilal, V. Puetter, C. Otto, K. Parczyk, and B. Bader, “A dual estrogen receptor TR-FRET assay for simultaneous measurement of steroid site binding and coactivator recruitment,” Journal of Biomolecular Screening, vol. 15, no. 3, pp. 268–278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. R. Gunther, Y. Du, E. Rhoden et al., “A set of time-resolved fluorescence resonance energy transfer assays for the discovery of inhibitors of estrogen receptor-coactivator binding,” Journal of Biomolecular Screening, vol. 14, no. 2, pp. 181–193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Jasuja, J. Ulloor, C. M. Yengo et al., “Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain,” Molecular Endocrinology, vol. 23, no. 8, pp. 1231–1241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Vivoli, H. R. Novak, J. A. Littlechild, and N. J. Harmer, “Determination of protein-ligand interactions using differential scanning fluorimetry,” Journal of Visualized Experiments, no. 91, Article ID e51809, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. J. F. Glickman, X. Wu, R. Mercuri et al., “A comparison of ALPHAscreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors,” Journal of Biomolecular Screening, vol. 7, no. 1, pp. 3–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Liu, K. S. Knappenberger, H. Käck et al., “A homogeneous in vitro functional assay for estrogen receptors: Coactivator recruitment,” Molecular Endocrinology, vol. 17, no. 3, pp. 346–355, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. M. S. Ozers, K. M. Ervin, C. L. Steffen et al., “Analysis of ligand-dependent recruitment of coactivator peptides to estrogen receptor using fluorescence polarization,” Molecular Endocrinology, vol. 19, no. 1, pp. 25–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Sonneveld, J. A. C. Riteco, H. J. Jansen et al., “Comparison of in vitro and in vivo screening models for androgenic and estrogenic activities,” Toxicological Sciences, vol. 89, no. 1, pp. 173–187, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Sedlák, A. Paguio, and P. Bartůněk, “Two panels of steroid receptor luciferase reporter cell lines for compound profiling,” Combinatorial Chemistry & High Throughput Screening, vol. 14, no. 4, pp. 248–266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Andruska, C. Mao, M. Cherian, C. Zhang, and D. J. Shapiro, “Evaluation of a luciferase-based reporter assay as a screen for inhibitors of estrogen-ERα-induced proliferation of breast cancer cells,” Journal of Biomolecular Screening, vol. 17, no. 7, pp. 921–932, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. C.-W. Hsu, J. Zhao, R. Huang et al., “Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor,” Scientific Reports, vol. 4, article no. 6437, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. A.-M. Krogsdam, C. A. F. Nielsen, S. Neve et al., “Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor δ-mediated transactivation,” Biochemical Journal, vol. 363, part 1, pp. 157–165, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. T. H.-W. Huang, A. W. Teoh, B.-L. Lin, D. S.-H. Lin, and B. Roufogalis, “The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome,” Pharmacological Research, vol. 60, no. 3, pp. 195–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Rigano, C. Sirignano, and O. Taglialatela-Scafati, “The potential of natural products for targeting PPARα,” Acta Pharmaceutica Sinica B (APSB), vol. 7, no. 4, pp. 427–438, 2017. View at Publisher · View at Google Scholar · View at Scopus